Physician- and Patient-based Barriers to NGS Testing

The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.

Trial Details

NCT ID
NCT07209176
Phase
NA
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Provider-level and patient education at end of study
  • Provider-level and patient-level
Locations (sample)
  • Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

  • men diagnosed with metastatic prostate cancer
  • seen by Johns Hopkins Medical Oncology as a new patient visit between January 1, 2025 and December 31, 2026

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →